A simple reverse transcriptase PCR assay to distinguish EBNA1 gene transcripts associated with type I and II latency from those arising during induction of the viral lytic cycle

Journal of Virology

Volumn 70, Issue 11, 1996, Pages 8204-8208

  Schaefer, Brian C ^a,b   Strominger, Jack L ^a   Speck, Samuel H ^c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; CELL NUCLEUS ANTIGEN EBNA 1; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; CYTOLYSIS; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; LATENT VIRUS INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; VIRUS GENOME;

EID: 0029826882     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.11.8204-8208.1996     Document Type: Article

References (29)

1. Chen, C. L., R. H. Sadler, D. M. Walling, I. J. Su, H. C. Hsieh, and N. Raab-Traub. 1993. Epstein-Barr virus gene expression in EBV-positive peripheral T-cell lymphomas. J. Virol. 67:6303-6308.
2. Chomczynski, P., and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
3. Deacon, E. M., G. Pallesen, G. Niedobilek, J. Crocker, L. Brooks, A. B. Rickinson, and L. S. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177:339-349.
4. Fahraeus, R., H. Li-Fu, I. Ernberg, J. Finke, M. Rowe, G. Klein, K. Falk, E. Nilsson, M. Yadaf, P. Busson, T. Tursz, and B. Kallin. 1988. Expression of the Epstein-Barr virus genome in nasopharyngeal carcinoma. Int. J. Cancer 42:329-338.
5. Gregory, C. D., M. Rowe, and A. B. Rickinson. 1990. Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J. Gen. Virol. 71:1481-1495.
6. Hitt, M., M. Allday, T. Hara, L. Karran, M. Jones, P. Busson, T. Tursz, I. Ernberg, and B. Griffin. 1989. EBV gene expression in an NPC-related tumour. EMBO J. 8:2639-2651.
7. Kawasaki, E. S. 1990. Amplification of RNA, p. 21-27. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, Inc., San Diego, Calif.
8. Kerr, B. M., A. L. Lear, M. Rowe, D. Croom-Carter, L. S. Young, S. M. Rookes, P. H. Gallimore, and A. B. Rickinson. 1992. Three transcriptionally distinct forms of Epstein-Barr virus latency in somatic cell hybrids: cell phenotype dependence of virus promoter usage. Virology 187:189-201.
9. Klein, G., L. Dombos, and B. Gothosokar. 1972. Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus. Int. J. Cancer 10:44-57.
10. Lear, A. L., M. Rowe, M. G. Kurilla, S. Lee, S. Henderson, E. Kieff, and A. B. Rickinson. 1992. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle. J. Virol. 66:7461-7468.
11. Levitskaya, J., M. Coram, V. Levitsky, S. Imreh, P. M. Steigerwald-Mullen, G. Klein, M. G. Kurilla, and M. G. Masucci. 1995. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature (London) 375:685-688.
12. Nonkwelo, C., J. Skinner, A. Bell, A. Rickinson, and J. Sample. 1996. Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J. Virol. 70:623-627.
13. Nonoyama, M., A. Tanaka, S. Silver, and R. Glaser. 1978. Transcription of EBV genomes in human lymphoblastoid cells and in somatic-cell hybrids of Burkitt's lymphoma. IARC (Int. Agency Res. Cancer) Sci. Publ. 24:559-563.
14. Pallesen, G., S. J. Hamilton-Dutoit, M. Rowe, and L. Young. 1991. Expression of the Epstein-Barr virus latent gene products in tumor cells of Hodgkin's disease. Lancet 337:320-322.
15. Rooney, C., M. Rowe, L. Wallace, and A. B. Rickinson. 1985. Epstein-Barr virus-positive Burkitt's lymphoma cells are not recognized by virus-specific T-cell surveillance. Nature (London) 317:629-631.
16. Rowe, D. T., M. Rowe, G. I. Evan, L. Wallace, P. J. Farrell, and A. B. Rickinson. 1986. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells. EMBO J. 5:2599-2607.
17. Rowe, M., and C. Gregory. 1989. Epstein-Barr virus and Burkitt's lymphoma. Adv. Viral Oncol. 8:237-259.
18. Rowe, M., D. Rowe, C. Gregory, L. S. Young, P. Farrell, H. Rupani, and A. B. Rickinson. 1987. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6:2743-2751.
19. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
20. Sample, J., L. Brooks, C. Sample, L. Young, M. Rowe, C. Gregory, A. Rickinson, and E. Kieff. 1991. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site. Proc. Natl. Acad. Sci. USA 88:6343-6347.
21. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. The Epstein-Barr virus BamHI F promoter is an early lytic promoter: lack of correlation with EBNA1 gene transcription in group I Burkitt's lymphoma cell lines. J. Virol. 69:5039-5047.
22. Schaefer, B. C., J. L. Strominger, and S. H. Speck. 1995. Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc. Natl. Acad. Sci. USA 92:10565-10569.
23. Schaefer, B. C., M. Woisetschlaeger, J. L. Strominger, and S. H. Speck. 1991. Exclusive expression of Epstein-Barr virus nuclear antigen 1 in Burkitt lymphoma arises from a third promoter, distinct from the promoters used in latently infected lymphocytes. Proc. Natl. Acad. Sci. USA 88:6550-6554.
24. Smith, P. R., and B. E. Griffin. 1992. Transcription of the Epstein-Barr virus gene EBNA-1 from different promoters in nasopharyngeal carcinoma and B-lymphoblastoid cells. J. Virol. 66:706-714.
25. Speck, S. H., and J. L. Strominger. 1989. Transcription of Epslein-Barr virus in latently infected, growth transformed lymphocytes. Adv. Viral Oncol. 8:133-150.
26. Takimoto, T., M. Kamide, and R. Umdea. 1984. Establishment of Epstein-Barr virus (EBV)-associated nuclear antigen (EBNA)-positive nasopharyngeal carcinoma hybrid cell line (NPC-KT). Arch. Oto-Rhino-Laryngol. 239: 87-92.
27. Woisetschlaeger, M., J. L. Strominger, and S. H. Speck. 1989. Mutually exclusive use of viral promoters in Epstein-Barr virus latently infected lymphocytes. Proc. Natl. Acad. Sci. USA 86:6498-6502.
28. Woisetschlaeger, M., C. N. Yandava, L. A. Furmanski, J. L. Strominger, and S. H. Speck. 1990. Promoter switching in Epstein-Barr virus during the initial stages of infection. Proc. Natl. Acad. Sci. USA 87:1725-1729.
29. Young, L., C. Dawson, D. Clark, H. Rupani, P. Busson, T. Tursz, A. Johnson, and A. B. Rickinson. 1988. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J. Gen. Virol. 69:1051-1065.